CANDEL THERAPEUTICS INC
CADLNASDAQ🏆 #2713 by market capEarnings Nov 5US Equity
$8.82▲ $0.14 (+1.61%)
Latest quoteTrack CADL
Get earnings, price moves & breaking news on Telegram
24h▲ 1.6%
7d▲ 5.3%
14d▼ 1.0%
30d▼ 19.0%
ytd▲ 55.8%
1y▲ 60.7%
🏦Market Cap
$675M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
40
Weak
Trading Snapshot
- Day Range
- $8.62 – $8.85
- 52-Week Range
- $4.35 – $14.00
- Volume (shares)
- 23,667
- Avg Volume (shares)
- —
- Shares Outstanding
- 76.5M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -5.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.19
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +54.4%
CANDEL THERAPEUTICS INC
CADLFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$48M▲ +44.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$39M▲ +43.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
54.9M▲ +54.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$118M▲ +$29M YoY
StockOtter · stockotter.spaceAbout CANDEL THERAPEUTICS INC
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100
Analyst Ratings
ⓘConsensus
Buy
15 analysts
Strong Buy5
Buy9
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.